Mark Lackner - 03 Feb 2025 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Reporting relationship: Chief Scientific Officer
Issuer ticker: ZNTL
Reported as of: 03 Feb 2025
Net transaction value: -$24,591
SEC form: 4
Accepted by SEC: 05 Feb 2025, 18:32:31 UTC
Prior SEC filing: 03 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrea Paul, attorney-in-fact for Mark Lackner

Key filing fact

Mark Lackner filed Form 4 for Zentalis Pharmaceuticals, Inc. (ZNTL) on 05 Feb 2025.

Key facts

This page summarizes Mark Lackner's Form 4 filing for Zentalis Pharmaceuticals, Inc. (ZNTL).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Feb 2025, 18:32.

Change

Previous filing in this sequence was filed on 03 Jan 2025.
Current net transaction value: -$24,591.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZNTL transaction

Common Stock

Award

Transaction value: $0
Shares: +335,907
Change %: +176%
Price: $0.000000
Shares after: 527,224
Date: 03 Feb 2025
Ownership: Direct
Footnotes: F1

ZNTL transaction

Common Stock

Sale

Transaction value: $24,591
Shares: -14,368
Change %: -2.7%
Price: $1.71
Shares after: 512,856
Date: 03 Feb 2025
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZNTL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +124,714
Change %
Price: $0.000000
Shares after: 124,714
Date: 03 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 124,714
Exercise price: $1.68
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer.

Footnote F2

This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.

Footnote F3

The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.